Cataract surgery significantly improves both distance and near vision in patients with neovascular age-related macular degeneration undergoing anti-vascular endothelial growth factor treatment ...

Target Audience The intended audience for this activity includes retina specialists and ophthalmologists involved in the management of patients with nAMD, DME, and MacTel.

New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon ...

Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD) ...

A single injection of ixoberogene soroparvovec reduced anti-VEGF injection needs by 90%-95% at 26 weeks in patients with neovascular age-related macular degeneration.